Cover Image
市場調查報告書

細胞免疫療法市場:2015∼2030年

T-Cell Immunotherapy Market, 2015-2030

出版商 ROOTS ANALYSIS 商品編碼 342155
出版日期 內容資訊 英文 419 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
細胞免疫療法市場:2015∼2030年 T-Cell Immunotherapy Market, 2015-2030
出版日期: 2015年10月13日 內容資訊: 英文 419 Pages
簡介

世界衛生組織 (WHO) 預測新癌症確診患者數在今後20年將增加70%,現在光美國每年就有超過100萬人罹患癌症。癌症治療藥也是研究開發活動最活絡的領域之一,但仍留下非常多的未滿足需求。在這種情況下近年來癌症免疫療法日益熱門,透過利用免疫系統,以癌細胞標的化的治療藥之開發計劃,逐漸在製藥業界內建立穩固的地位。尤其免疫檢查點抑制劑的成功下出現的T細胞免疫治療,更成了可望在標的特異性、商應性、記憶體形成能力等方面具有出色特長的利用T細胞之創新治療法而輩受注目。

本報告提供投入市場產品中不存在黎明期,最早受人注目的T細胞免疫療法市場之主要企業的動向及開發平台產品之開發階段、研究開發合作動向、創新技術、投資動向、成為焦點的各療領域、競爭狀況、產品化預測等分析,同時也收錄主要製造商幹部的採訪。

第1章 序論

第2章 摘要整理

第3章 簡介

  • 癌症治療的4個柱子
  • 免疫療法:建立穩固的地盤
  • 癌症免疫療法
  • 癌症免疫療法的種類
    • 各作用機制
    • 各標的類型
    • 方法別
    • 各級產品
  • T細胞療法:演進的過程
  • T細胞療法:重要課題
  • T細胞重定向策略
  • T細胞Transduction / Transfection 的方法
  • T細胞療法的治癒可能性
  • T細胞療法的障礙

第4章 市場的狀況

  • 簡介
  • T細胞療法領域的演進
  • 有前途的開發平台
  • 成為市場開發先導角色的嵌合抗原受體表現T細胞 (CAR-T) 療法
  • 學術研究領導T細胞療法的研究開發活動
  • 預測將擴大的T細胞療法市場
  • 少數成功案例
  • 在T細胞療法市場有活躍趨勢的企業
  • CAR-T療法上CD19仍然是最常見的標的
  • 對應T細胞受體 (TCR) 療法明確區分的標的
  • 目前開發中的各種T細胞免疫療法

第5章 嵌合抗原受體表現T細胞療法

  • 簡介
  • 開發的過程
  • 研究現況
  • 嵌合抗原受體的解剖學配置
  • 嵌合抗原受體的生成
  • CAR-T細胞的開發
  • 淋巴球乾涸療法
  • 通用CAR-T細胞
  • 投藥的途徑
  • 毒性問題
  • 毒性問題的對應
  • CD19:富有魅力的標的
  • 其他的標的
  • 以CAR-T療法為中心的課題
  • CTL019 (Novartis)
  • JCAR (Juno Therapeutics)
  • KTE-C19 (Kite Pharma)
  • CD19 CAR (TaKaRa BIO)
  • EFGRvIII CAR (Kite Pharma)

第6章 T細胞受體 (TCR) 療法

  • 簡介
  • T細胞受體結構
  • CAR和TCR的差異
  • 開發的過程
  • 研究現況
  • 作用機制
  • 安全性的問題
  • 抗原特異性T細胞受體的必要條件
  • 強化抗癌症效果策略的明確化
  • NY-ESO-1 TCR (Kite Pharma)
  • MAGE A3/A6 TCR (Kite Pharma)
  • JTCR016 (Juno Therapeutics)
  • IMCgp100 (Immunocore)

第7章 基於腫瘤浸潤淋巴球 (TIL) 的治療方法

  • 簡介
  • 至今發展過程
  • 研究現況
  • 現在研究推動的強化功效策略
  • LN-144 (舊名Contego) (Lion Biotechnologies)

第8章 市場機會

  • 本章概要
  • 調查範圍
  • 預測方法
  • T細胞療法整體市場的預測,2015∼2030年
  • CAT-T療法整體市場狀況
  • TCR療法整體市場狀況
  • TIL療法整體市場狀況

第9章 T細胞療法主要的治療領域

  • 本章概要
  • 簡介
  • 骨髓惡性腫瘤
    • 白血病和淋巴瘤
    • 多發性骨髓瘤
  • 固態腫瘤
    • 轉移性黑色素瘤
    • 膀胱癌
    • 腎臟癌症
    • 卵巢癌症
    • 乳癌
    • 膠芽細胞瘤

第10章 最新的技術

  • 本章概要
  • 簡介
  • 促進T細胞療法發展的基因編輯技術
  • 基因編輯技術的應用
  • 透過改善特性的T細胞療法之設計

第11章 創業投資的支援

  • 本章概要
  • 投資者和創新的治療方法
  • 投資/津貼範例
  • 高漲的創業投資的關心
  • 資金籌措範例
  • 資金籌措的數量

第12章 主要企業簡介

  • 本章概要
  • Adaptimmune
  • Altor Bioscience Corporation
  • bluebird bio
  • Cellectis
  • Cell Therapy Catapult
  • Juno Therapeutics
  • Kite Pharma
  • Lion Biotechnologies
  • Novartis
  • TaKaRa BIO
  • Unum Therapeutics
  • 其他企業
    • Bellicum Pharmaceuticals
    • Cellular Biomedicine Group

第13章 主要企業幹部的採訪

第14章 結論

第15章 附錄

  • 附錄1:表格形式的資料
  • 附錄2:企業和組織一覽

圖表

目錄
Product Code: RA10047

WHO has stated that the number of new cancer cases is expected to rise by 70% in the coming two decades. In the US alone, over one million people are diagnosed with cancer each year. Although cancer therapeutics continues to be one of the most active areas in terms of drug development, there is still a significant unmet need. Specifically, immuno-oncology has been gradually nurtured by researchers over the last several years. Post an evident shift towards the development of therapeutics targeting cancer cells by harnessing immune system components, immunotherapeutics have gained a strong foothold in the pharmaceutical industry. After the early success of Immune Checkpoint Inhibitors, T-cell immunotherapy has emerged as another innovative and potent arm of this market.

Characterised by key features such as target specificity, adaptability and memory, T-cells have been effectively used as tools to mediate an immune response. T-cell immunotherapy is structured into segments comprising of CAR-T, TCR and TIL therapies. Academicians across the globe have significantly contributed by convening the initial research of the candidates; this has served as the framework for several start-ups / established industry players to drive the research forward.

The overall market is expected to make a huge leap over the coming decade. It is also important to highlight that various technology providers, aiming to develop T-cell immunotherapy products with improved efficacy and safety, have developed innovative platforms for engineering of the T-cells. Innovative research, lucrative rounds of VC funding, discovery of several novel targets, growing pipelines directed towards different therapeutic areas and encouraging clinical trial results have emerged as some of the other drivers of this market.

The “T-Cell Immunotherapy Market, 2015-2030” report provides an extensive study of the field of T-cell immunotherapy. With no marketed products, this emerging field is still in its infancy; the report provides a comprehensive view of the market segmented into the following three sub-groups: CAR-T therapies, TCR therapies and TIL therapies.

The market is characterised by a robust and opportunistic pipeline of products targeting both haematological cancers and solid tumours. As mentioned earlier, several research institutes have played a critical role in progression of the technology to its current stage. Post the initial research, industry players have collaborated with non-industry participants to fund the clinical and commercial development of these products. Some late stage products that have emerged out of such collaborations include CTL-019 (Novartis/University of Pennsylvania / The Children's Hospital of Philadelphia), JCAR017 (Juno Therapeutics / Seattle Children's Hospital), KTE-C19 and NY-ESO-1 TCR (Kite Pharma / National Cancer Institute), CD19-CAR (Takara Bio / Jichi Medical University) and LN-144 (Lion Biotechnologies / National Cancer Institute). Encouraging clinical results have accelerated the progress of these therapies as they have emerged as one of the most effective ways of leveraging the potential of immune system.

The market is also seeing a growing interest from several technology providers, especially those with capabilities in genome editing and viral and non-viral gene transfer. In addition, several T-cell immunotherapy companies and technology providers are also developing innovative safety switches to manage known side effects such as cytokine release syndrome and B-cell aplasia.

One of the key objectives of the study is to review and quantify the opportunities laid by the innovative programs of both small and big pharma firms. The unexploited and promising nature of this market supports the hopes pinned on multiple start-ups by several strategic investors and venture capital firms. Amongst other elements, the report elaborates on the following key areas:

  • The current state of the market with respect to key players, development stage of pipeline products (both clinical / preclinical) and targeted indications
  • Partnerships which have taken place in the recent past covering research and development collaborations, manufacturing agreements, license agreements specific to technology platforms, product co-development and co-commercialisation
  • Innovative technological platforms, such as safety switches, which have contributed significantly in overcoming the existing gaps in therapy regimen
  • Various investments and grants received by the companies focused in this area
  • Therapeutic areas forming the current focus of developers, the gradual drift and opportunity offered by non-oncological therapeutic areas
  • Competitive landscape, challenges and expected trend of market evolution within the three sub-segments
  • Development and sales potential based on target consumer segments, likely adoption rate and expected pricing

The research, analysis and insights presented in this report include potential sales of several CAR-T therapies, TCR therapies and TIL therapies; this analysis is backed by a deep understanding of key drivers behind the growth. With most products still in the early stage of development, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution. All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • During the course of our research, we identified over 180 T-cell therapies across various phases of development; CAR-T therapies (56%) are the most common, followed by TCR (25%) and TIL (19%) therapies.
  • Research institutions, through investment of time, expertise and effort, have played a critical role in the design and development of novel CAR-Ts, TCRs and TILs. In fact, non-industrial players are involved in the development of around 65% of all the molecules in the pipeline; of these, 23% molecules are being developed jointly with industry participants.
  • Kite Pharma is the current flag-bearer; Novartis, Juno Therapeutics, CBMG, Celyad, Lion Biotechnologies, Immunocore and Adaptimmune are some other well-known players. In addition, several start-ups have also emerged; these include (in alphabetical order) Altor BioScience, Applied Immune Technologies, Autolus, Carsgen, Celdara Medical, Eureka Therapeutics, Formula Pharmaceuticals, Mustang Therapeutics, Theravectys, TILT Biotherapeutics and TNK Therapeutics.
  • Engineered CAR-Ts with switch technologies are amongst the latest addition to the next-generation of T-cell immunotherapy pipeline. Players are developing CAR-Ts, TCRs and TILs which are more advanced and shall cater to a diverse array of patient needs. The coming few years are likely to witness a wave of innovative and successful T-cell therapies.
  • Funding from VC firms and strategic investors has been a key enabler to the market's growth. Over the last six years, we identified investments close to USD 3 billion across several start-ups and small firms; this trend is unlikely to subside in the near future.
  • Overall, we believe the T-cell therapy market will be worth USD 30 billion by 2030, expanding at an annualised growth rate of over 100%; as TCR and TIL therapies gain ground, CAR-T therapies are likely to garner the most attention in near future.

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 presents an executive summary of the report. It offers a high level view on where the T-cell immunotherapy market is headed in the mid-long term.

Chapter 3 provides a general introduction to T-cell immunotherapy. In this section, we have briefly discussed the conventional therapies being used for oncology treatment, the advent of cancer immunotherapy and the reasons supporting the gradual emergence of T-cell therapies.

Chapter 4 provides a comprehensive landscape of the T-cell immunotherapy market. It includes information on therapies which are currently in different stages of development (both clinical and preclinical/discovery). The detailed analysis of this pipeline includes information on most commonly targeted indications, current phases of development, the targets and the type of developers for each of the therapies.

Chapter 5 focuses on CAR-T based therapies and highlights the prevailing trends pertaining to the on-going research in this field. It discusses the targets under investigation, current challenges, toxicity issues and several other relevant parameters. To credit the work of the eminent researchers across the globe, we have provided a mapping of prominent key opinion leaders in the CAR-T space. The chapter includes detailed profiles of the drugs under development. These profiles cover information such as history of development, clinical trial timeline, clinical trial results, manufacturing, estimated cost of treatment and treatment regimen.

Chapter 6 elaborates on TCR based therapies and highlights the current scenario pertaining to the on-going research in this field. As with the CAR-T therapies, to credit the work of eminent researchers across the globe, we have provided a mapping of prominent key opinion leaders in the TCR space. The chapter also includes detailed drug profiles of several drugs under development.

Chapter 7 elaborates on the TIL based therapies. As in the earlier two chapters, we have mapped the prominent key opinion leaders in the TIL space. The chapter also includes detailed profiles of the drugs under development.

Chapter 8 elaborates on the monetary opportunity presented by these therapies. It provides a comprehensive market forecast analysis for molecules in advanced stages of development (phase I/II, phase II and phase II/III) taking into consideration the target patient population, competition, likely adoption rate and price points.

Chapter 9 provides a competitive landscape of various T-cell therapies being developed for the treatment of commonly targeted indications such as haematological cancers and solid tumours. These indications have been the prime focus of companies developing T-cell immunotherapies. The chapter also highlights the epidemiological facts and currently available treatments for each indication.

Chapter 10 talks about emerging technological platforms which mediate/assist the growth of the T-cell market. It includes a detailed discussion on such novel and innovative technologies, along with brief information about the technology providers.

Chapter 11 presents details on various investments and grants received by companies focused in the area of T-cell immunotherapy. The analysis highlights the growing interest from the VC community and other strategic investors.

Chapter 12 provides detailed company profiles of the leading players in the market. Each company profile includes information such as financial performance, geographical presence, T-cell immunotherapy pipeline, recent collaborations and developments. Additionally, we have also provided details about funding instances relevant to each player.

Chapter 13 is a collection of transcripts of interviews conducted during the course of this study.

Chapter 14 summarises the overall report. In this chapter, we have provided a list of key takeaways and have expressed our independent opinion based on the research and analysis described in previous chapters.

Chapters 15 is an appendix, which provides tabulated data and the list of companies covered in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. The Four Pillars of Cancer Therapy
  • 3.3. Immunotherapy: Gaining a Strong Foothold
  • 3.4. Immuno-Oncology (Cancer Immunotherapy)
  • 3.5. Classification of Cancer Immunotherapies
    • 3.5.1. By Mechanism of Action
      • 3.5.1.1. Active Immunotherapy
      • 3.5.1.2. Passive Immunotherapy
    • 3.5.2. By Type of Target
    • 3.5.3. By Approach
      • 3.5.3.1 Activation and Suppression Immunotherapy
    • 3.5.4. By Product Class
      • 3.5.4.1. Monoclonal Antibodies
      • 3.5.4.2. Bispecific Antibodies
      • 3.5.4.3. Cytokines
      • 3.5.4.4. Cell Based Therapies
  • 3.6. T-Cell Therapies: Historical Evolution
  • 3.7. T-Cell Therapies: Key Considerations
  • 3.8. Strategies for Redirection of T-Cells
  • 3.9. Methodologies for Transduction / Transfection of T-Cells
    • 3.9.1. Retroviral Vectors
    • 3.9.2. Lentiviral Vectors
    • 3.9.3. Sleeping Beauty Transposon
  • 3.10. Curative Potential of T-Cell Therapies
  • 3.11. Roadblocks for T-Cell Therapies

4. MARKET LANDSCAPE

  • 4.1. Introduction
  • 4.2. Evolving T-Cell Therapy Space
  • 4.3. T-Cell Therapy: A Promising and Robust Pipeline
  • 4.4. CAR-T Cells Spearhead the T-Cell Market
  • 4.5. Academia Research Leads On-going Activity in the T-Cell Space
  • 4.6. T-Cell Market Poised to Expand Further: Several Molecules in Early Phases of Development
  • 4.7. LimitedSuccess So Far: Restricted to Haematological Cancers/ Solid Tumours
  • 4.8. Active Industry Players in the T-Cell Therapy Market
  • 4.9. CD19 Continues to be the Most Popular Target for CAR-T Therapies
  • 4.10. Targets Well Distributed for TCR Therapies
  • 4.11. Other T-Cell Immunotherapies under Development

5. CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY

  • 5.1. Introduction
  • 5.2. History of Development
  • 5.3. Current Research Landscape
  • 5.4. Anatomical Layout of Chimeric Antigen Receptor
  • 5.5. Generations of Chimeric Antigen Receptors
  • 5.6. Development of CAR-T Cells
  • 5.7. Lymphodepleting Therapy
  • 5.8. Universal CAR-Ts
  • 5.9. Route of Administration
  • 5.10. Toxicity Issues
    • 5.10.1. Cytokine Release Syndrome (CRS)
    • 5.10.2. On-Target Off-Tumour Toxicity
    • 5.10.3. Encephalopathy and B-Cell Aplasia
  • 5.11. Management of Toxicity Issues
    • 5.11.1. Target Selection
    • 5.11.2. Cell Persistence
    • 5.11.3. Receptor Expression
  • 5.12. CD19: An Attractive Target
  • 5.13. Other Targets
  • 5.14. Challenges Associated with CAR-T Therapy
    • 5.14.1. Competitive Risks
    • 5.14.2. Clinical Risks
    • 5.14.3. Regulatory Challenges
    • 5.14.4. Commercial Risks
  • 5.15. CTL019 (Novartis)
    • 5.15.1. Introduction
    • 5.15.2. History of Development
    • 5.15.3. Development Status
    • 5.15.4. Key Clinical Trial Results
    • 5.15.5. Dosage Regimen, Treatment Cost and Manufacturing
  • 5.16. JCAR (Juno Therapeutics)
    • 5.16.1. Introduction
    • 5.16.2. CAR-T Design
    • 5.16.3. Development Status
    • 5.16.4. Key Clinical Trial Results
      • 5.16.4.1. JCAR014
      • 5.16.4.2. JCAR015
      • 5.16.4.3. JCAR017
    • 5.16.5. Dosage Regimen and Manufacturing
  • 5.17. KTE-C19 (Kite Pharma)
    • 5.17.1. Introduction
    • 5.17.2. Development Status
    • 5.17.3. Key Clinical Trial Results
    • 5.17.4. Dosage Regimen and Manufacturing
    • 5.17.5. Next Generation eACT CAR Candidates
  • 5.18. CD19 CAR (Takara Bio)
    • 5.18.1. Introduction
    • 5.18.2. Development Status
    • 5.18.3. Key Clinical Trial Results
    • 5.18.4. Dosage Regimen and Manufacturing
  • 5.19. EFGRvIII CAR (Kite Pharma)
    • 5.19.1. Introduction
    • 5.19.2. Development Status
    • 5.19.3. Dosage Regimen and Manufacturing

6. T-CELL RECEPTOR (TCR) THERAPIES

  • 6.1. Introduction
  • 6.2. Structure of T-Cell Receptor
  • 6.3. Difference between CAR and TCR
  • 6.4. History of Development
  • 6.5. Current Research Landscape
  • 6.6. Mechanism of Action
  • 6.7. Safety Issues
    • 6.7.1. Insertional Mutagenesis
    • 6.7.2. On-Target Off-Tumour Toxicity
    • 6.7.3. Cross Reactivity Issues
    • 6.7.4. TCR Mismatch Pairing
  • 6.8. Prerequisites of Antigen-Specific T-Cell Receptors
  • 6.9. Identifying Strategies that Enhance the Anti-Tumour Efficacy
    • 6.9.1. Affinity Enhanced TCRs
    • 6.9.2. Soluble TCR Based Biologics
  • 6.10. NY-ESO-1 TCR (Kite Pharma)
    • 6.10.1. Introduction
    • 6.10.2. Development Status
    • 6.10.3. Dosage Regimen
  • 6.11. MAGE A3/A6 TCR (Kite Pharma)
    • 6.11.1. Introduction
    • 6.11.2. Development Status
    • 6.11.3. Dosage Regimen
  • 6.12. JTCR016 (Juno Therapeutics)
    • 6.12.1. Introduction
    • 6.12.2. Development Status
    • 6.12.3. Key Clinical Trial Results
    • 6.12.4. Dosage Regimen
  • 6.13. IMCgp100 (Immunocore)
    • 6.13.1. Introduction
    • 6.13.2. Development Status
    • 6.13.3. Key Clinical Trial Results
    • 6.13.4. Dosage Regimen

7. TUMOUR INFILTRATING LYMPHOCYTES (TIL) BASED THERAPIES

  • 7.1. Introduction
  • 7.2. Historical Background
  • 7.3. Current Research Landscape
  • 7.4. Strategies under Research to Enhance Efficacy
  • 7.5. TIL: A Prognostic Tool for Various Indications
  • 7.6. LN-144 (Formerly Contego) (Lion Biotechnologies)
    • 7.6.1. Introduction
    • 7.6.2. Development Status
    • 7.6.3. Key Clinical Trial Results
    • 7.6.4. Dosage Regimen and Manufacturing
    • 7.6.5. Patent Portfolio

8. MARKET OPPORTUNITY

  • 8.1. Chapter Overview
  • 8.2. Scope and Limitations
  • 8.3. Forecast Methodology
  • 8.4. Overall T-Cell Therapy Market, 2015-2030
  • 8.5. Overall Chimeric Antigen Receptor T-Cell (CAR-T) Market
    • 8.5.1. CTL019 (Novartis)
      • 8.5.1.1. Target Population
      • 8.5.1.2. Sales Forecast
    • 8.5.2. KTE-C19 (Kite Pharma)
      • 8.5.2.1. Target Population
      • 8.5.2.2. Sales Forecast
    • 8.5.3. CD19 CAR-T (Takara Bio)
      • 8.5.3.1. Target Population
      • 8.5.3.2. Sales Forecast
    • 8.5.4. EGFR CAR-T (Cellular Biomedicine Group)
      • 8.5.4.1. Target Population
      • 8.5.4.2. Sales Forecast
    • 8.5.5. CD30 CAR-T (Cellular Biomedicine Group)
      • 8.5.5.1. Target Population
      • 8.5.5.2. Sales Forecast
    • 8.5.6. Anti-CD19 CAR-T VectorTransducedT-Cells (Cellular Biomedicine Group)
      • 8.5.6.1. Target Population
      • 8.5.6.2. Sales Forecast
    • 8.5.7. Anti-CD20 CAR T VectorTransduced T-Cells (Cellular Biomedicine Group)
      • 8.5.7.1. Target Population
      • 8.5.7.2. Sales Forecast
    • 8.5.8. CD19 EBV CAR-T (Autolus)
      • 8.5.8.1. Target Population
      • 8.5.8.2. Sales Forecast
    • 8.5.9. EGFRvIII (Kite Pharma)
      • 8.5.9.1. Target Population
      • 8.5.9.2. Sales Forecast
    • 8.5.10. JCAR017 (Juno Therapeutics)
      • 8.5.10.1. Target Population
      • 8.5.10.2. Sales Forecast
    • 8.5.11. JCAR0XX (Juno Therapeutics)
      • 8.5.11.1. Target Population
      • 8.5.11.2. Sales Forecast
  • 8.6. Overall TCR Market
    • 8.6.1. IMCgp100 (Immunocore)
      • 8.6.1.1. Target Population
      • 8.6.1.2. Sales Forecast
    • 8.6.2. NY-ESO-1 TCR (Kite Pharma)
      • 8.6.2.1. Target Population
      • 8.6.2.2. Sales Forecast
    • 8.6.3. HPV-16 E6-TCR (Kite Pharma)
      • 8.6.3.1. Target Population
      • 8.6.3.2. Sales Forecast
    • 8.6.4. NY-ESO-1 TCR (Adaptimmune)
      • 8.6.4.1. Target Population
      • 8.6.4.2. Sales Forecast
    • 8.6.5. ALT-801 (Altor BioScience)
      • 8.6.5.1. Target Population
      • 8.6.5.2. Sales Forecast
    • 8.6.6. WT-1 TCR (Cell Therapy Catapult)
      • 8.6.6.1. Target Population
      • 8.6.6.2. Sales Forecast
    • 8.6.7. JTCR016 (Juno Therapeutics)
      • 8.6.7.1. Target Population
      • 8.6.7.2. Sales Forecast
    • 8.6.8. MAGE A3/A6 (Kite Pharma)
      • 8.6.8.1. Target Population
      • 8.6.8.2. Sales Forecast
    • 8.6.9. MAGE A3 (Kite Pharma)
      • 8.6.9.1. Target Population
      • 8.6.9.2. Sales Forecast
  • 8.7. Overall TIL Therapy Market
    • 8.7.1. LN-144 (Lion Biotechnologies)
      • 8.7.1.1. Target Population
      • 8.7.1.2. Sales Forecast
    • 8.7.2. TIL Therapy (Nantes University)
      • 8.7.2.1. Target Population
      • 8.7.2.2. Sales Forecast
    • 8.7.3. TIL Therapy (Netherlands Cancer Institute)
      • 8.7.3.1. Target Population
      • 8.7.3.2. Sales Forecast

9. KEY THERAPEUTIC AREAS FOR T-CELL THERAPIES

  • 9.1. Chapter Overview
  • 9.2. Introduction
  • 9.3. Haematological Malignancies
    • 9.3.1. Leukaemia and Lymphoma
      • 9.3.1.1. Introduction and Epidemiology: Leukaemia
        • 9.3.1.1.1. Acute Myeloid Leukaemia (AML)
        • 9.3.1.1.2. Chronic Myeloid Leukaemia (CML)
        • 9.3.1.1.3. Acute Lymphocytic Leukaemia (ALL)
        • 9.3.1.1.4. Chronic Lymphocytic Leukaemia (CLL)
      • 9.3.1.2. Introduction and Epidemiology: Lymphoma
      • 9.3.1.3. Current Treatment Landscape
        • 9.3.1.3.1. Targeted Therapies
      • 9.3.1.4. T-Cell Immunotherapy and Research Landscape
        • 9.3.1.4.1. CAR-Ts and Leukaemia/Lymphoma
        • 9.3.1.4.2. TCRs and Leukaemia/Lymphoma
    • 9.3.2. Multiple Myeloma
      • 9.3.2.1. Introduction and Epidemiology
      • 9.3.2.2. Current Treatment Landscape
      • 9.3.2.3. T-Cell Immunotherapy and Research Landscape
  • 9.4. Solid Tumours
    • 9.4.1. Metastatic Melanoma
      • 9.4.1.1. Introduction and Epidemiology
      • 9.4.1.2. Current Treatment Landscape
      • 9.4.1.3. T-Cell Immunotherapy and Research Landscape
        • 9.4.1.3.1. TILs and Metastatic Melanoma
        • 9.4.1.3.2. TIL Research at MD Cancer Research Centre, USA
        • 9.4.1.3.3. TIL Research at Sheba Medical Centre, Israel
        • 9.4.1.3.4. TCRs and Metastatic Melanoma
        • 9.4.1.3.5 CAR-Ts and Metastatic Melanoma
    • 9.4.2. Bladder Cancer
      • 9.4.2.1. Introduction and Epidemiology
      • 9.4.2.2. Current Treatment Landscape
      • 9.4.2.3. T-Cell Immunotherapy and Research Landscape
    • 9.4.3. Kidney Cancer
      • 9.4.3.1. Introduction and Epidemiology
      • 9.4.3.2. Current Treatment Landscape
      • 9.4.3.3. T-Cell Immunotherapy and Research Landscape
    • 9.4.4. Ovarian Cancer
      • 9.4.4.1. Introduction and Epidemiology
      • 9.4.4.2. Current Treatment Landscape
      • 9.4.4.3. T-Cell Immunotherapy and Research Landscape
        • 9.4.4.3.1. CAR-Ts and Ovarian Cancer
        • 9.4.4.3.2. TCRs and Ovarian Cancer
    • 9.4.5. Breast Cancer
      • 9.4.5.1. Introduction and Epidemiology
      • 9.4.5.2. Current Treatment Landscape
      • 9.4.5.3. T-Cell Immunotherapy and Research Landscape
        • 9.4.5.3.1. CAR-Ts and Breast Cancer
        • 9.4.5.3.2. TCRs and Breast Cancer
        • 9.4.5.3.3. TILs and Breast Cancer
    • 9.4.6. Glioblastoma
      • 9.4.6.1. Introduction and Epidemiology
      • 9.4.6.2. Current Treatment Landscape
      • 9.4.6.3. T-Cell Immunotherapy and Research Landscape

10. EMERGING TECHNOLOGIES

  • 10.1. Chapter Overview
  • 10.2. Introduction
  • 10.3. Genome Editing Driving the T-Cell Therapies
  • 10.4. Applications of Genome Editing
    • 10.4.1. Genome Editing Technologies
      • 10.4.1.1. CRISPR/Cas9 System
        • 10.4.1.1.1. Structural Features
        • 10.4.1.1.2. Modularity of the System
        • 10.4.1.1.3. Mechanism of Action
        • 10.4.1.1.4. Targeting Efficiency and Challenges
        • 10.4.1.1.5. Next-GEN CRISPR Technology
        • 10.4.1.1.6. Technology Providers
          • 10.4.1.1.6.1. Editas Medicine
          • 10.4.1.1.6.2 Intellia Therapeutics
          • 10.4.1.1.6.3. CRISPR Therapeutics
      • 10.4.1.2. TALENs
        • 10.4.1.2.1. Structural Features
        • 10.4.1.2.2. Mechanism of Action
        • 10.4.1.2.3. Advantages and Challenges
        • 10.4.1.2.4. Technology Providers
          • 10.4.1.2.4.1. Cellectis
          • 10.4.1.2.4.2. Editas Medicine
      • 10.4.1.3. Endonuclease and megaTAL
        • 10.4.1.3.1. Technology Providers
          • 10.4.1.3.1.1 bluebird bio
      • 10.4.1.4. Zinc Finger Nuclease
        • 10.4.1.4.1. Benefits
        • 10.4.1.4.2. Technology Providers
          • 10.4.1.4.2.1. Sangamo Biosciences
  • 10.5. Designing T-Cell Therapies with ImprovedCharacteristics
    • 10.5.1. Technology for Targeting Multiple Cancers
      • 10.5.1.1. Antibody Coupled T-Cell Receptor, UnumTherapeutics
      • 10.5.1.2. NK Cell Receptor, Celyad
        • 10.5.1.2.1. Long Term Tumour free Survival
        • 10.5.1.2.2. Durable Anti-Tumour Immunity
    • 10.5.2. Technology for Improved Safety
      • 10.5.2.1. Armoured CAR, Juno Therapeutics
      • 10.5.2.2. RheoSwitch Therapeutic System, Intrexon
      • 10.5.2.3. Inducible Caspase9 Safety Switch, BellicumPharmaceuticals
        • 10.5.2.3.1. CaspaCIDe Safety Switch Technology
        • 10.5.2.3.2. CIDeCAR Switch Technology
        • 10.5.2.3.3. GoCAR-T Switch Technology
      • 10.5.2.4. On-Off Switch, Multiple Companies
        • 10.5.2.4.1. Inhibitory CAR (iCAR), Juno Therapeutics
        • 10.5.2.4.2. On-Off Switch, Theravectys
    • 10.5.3. Allogeneic Technology
      • 10.5.3.1. CIK CAR-T Cells, Formula Pharmaceuticals
      • 10.5.3.2. Allogeneic Platform, Celyad
      • 10.5.3.3. Allogeneic Platform, Cellectis

11. VENTURE CAPITAL SUPPORT

  • 11.1. Chapter Overview
  • 11.2. Investors and Innovative Therapies: Trending Together
  • 11.3. Instances of Investments / Grants in T-Cell Therapies
  • 11.4. Growing Venture Capitalist Interest
  • 11.5. Funding Instances: Distribution by Type ofFunding
  • 11.6. Funding Amount: Distribution by Type of Funding

12. COMPANY PROFILES

  • 12.1. Chapter Overview
  • 12.2. Adaptimmune
    • 12.2.1. Company Overview
    • 12.2.2. Financial Information
    • 12.2.3. Product Portfolio
    • 12.2.4. Manufacturing Capabilities
    • 12.2.5. Collaborations
      • 12.2.5.1. Progenitor Cell Therapy
      • 12.2.5.2. Thermofisher / Life Technologies
      • 12.2.5.3. GlaxoSmithKline
    • 12.2.6. Future Outlook
  • 12.3. Altor Bioscience Corporation
    • 12.3.1. Company Overview
    • 12.3.2. Financial Information
    • 12.3.3. Product Portfolio
    • 12.3.4. Patents Portfolio
    • 12.3.5. Collaborations
      • 12.3.5.1. Massachusetts General Hospital and Howard Hughes Medical Institute
    • 12.3.6. Future Outlook
  • 12.4. bluebird bio
    • 12.4.1. Company Overview
    • 12.4.2. Financial Information
    • 12.4.3. Product Portfolio
    • 12.4.4. Collaborations
      • 12.4.4.1. Celgene Corporation
      • 12.4.4.2. Pregenen
      • 12.4.4.3. Five Prime Therapeutics
      • 12.4.4.4. Kite Pharma
    • 12.4.5. Future Outlook
  • 12.5. Cellectis
    • 12.5.1. Company Overview
    • 12.5.2. Financial Information
    • 12.5.3. Product Portfolio
    • 12.5.4. Collaborations
      • 12.5.4.1. CELLforCURE
      • 12.5.4.2. OncoDesign Biotechnology
      • 12.5.4.3. Ohio University
      • 12.5.4.4. Weill Cornell Medical College
    • 12.5.5. Future Outlook
  • 12.6. Cell Therapy Catapult
    • 12.6.1. Company Overview
    • 12.6.2. Product Portfolio
    • 12.6.3. Manufacturing Capabilities
    • 12.6.4. Collaborations
      • 12.6.4.1. UCL and Imperial Innovations
      • 12.6.4.2. Cellular Therapeutics
    • 12.6.5. Future Outlook
  • 12.7. Juno Therapeutics
    • 12.7.1. Company Overview
    • 12.7.2. Financial Information
    • 12.7.3. Product Portfolio
    • 12.7.4. Patent Litigation
    • 12.7.5. Manufacturing Capabilities
    • 12.7.6. Collaborations
      • 12.7.6.1. Memorial Sloan Kettering, Fred Hutchinson CancerCenter, Seattle Children's Research Institute
      • 12.7.6.2. Opus Bio
      • 12.7.6.3. MedImmune/AstraZeneca
      • 12.7.6.4. Stage Cell Therapeutics
      • 12.7.6.5. Editas Medicine
      • 12.7.6.6. Fate Therapeutics
      • 12.7.6.7. X-Body
      • 12.7.6.8. Celgene
    • 12.7.7. Future Outlook
  • 12.8. Kite Pharma
    • 12.8.1. Company Overview
    • 12.8.2. Financial Information
    • 12.8.3. Product Portfolio
    • 12.8.4. Manufacturing Capabilities
    • 12.8.5. Collaborations
      • 12.8.5.1. National Cancer Institute / National Institutes ofHealth
      • 12.8.5.2. Cabaret Biotech
      • 12.8.5.3. NeoStem
      • 12.8.5.4. Amgen
      • 12.8.5.5. Tel Aviv Sourasky Medical Center
      • 12.8.5.6. T-Cell Factory B.V. (TCF)
      • 12.8.5.7. bluebird bio
      • 12.8.5.8. Leukemia and Lymphoma Society
    • 12.8.6. Future Outlook
  • 12.9. Lion Biotechnologies
    • 12.9.1. Company Overview
    • 12.9.2. Financial Information
    • 12.9.3. Product Portfolio
    • 12.9.4. Manufacturing Capabilities
    • 12.9.5. Collaborations
      • 12.9.5.1. Lonza
      • 12.9.5.2. Moffitt Cancer Center
      • 12.9.5.3. National Cancer Institute
      • 12.9.5.4. National Institutes of Health
    • 12.9.6. Upcoming Products: Next Generation TILs
    • 12.9.7. Future Outlook
  • 12.10. Novartis
    • 12.10.1. Company Overview
    • 12.10.2. Financial Information
    • 12.10.3. Product Portfolio
    • 12.10.4. Patent Litigation
    • 12.10.5. Manufacturing Capabilities
    • 12.10.6. Collaborations
      • 12.10.6.1. University Of Pennsylvania
      • 12.10.6.2. Oxford BioMedica
      • 12.10.6.3. Intellia Therapeutics and Caribou Sciences
    • 12.10.7. Future Outlook
  • 12.11. Takara Bio
    • 12.11.1. Company Overview
    • 12.11.2. Financial Information
    • 12.11.3. Product Portfolio
    • 12.11.4. Manufacturing Capabilities
    • 12.11.5. Collaborations
      • 12.11.5.1. Memorial Sloan Kettering Cancer Center
      • 12.11.5.2. Jichi Medical University Hospital
    • 12.11.6. Future Outlook
  • 12.12. Unum Therapeutics
    • 12.12.1. Company Overview
    • 12.12.2. Financial Information
    • 12.12.3. Product Portfolio
    • 12.12.4. Collaborations
    • 12.12.5. Future Outlook
  • 12.13. Other Companies
    • 12.13.1. Bellicum Pharmaceuticals
    • 12.13.2. Cellular Biomedicine Group
      • 12.13.2.1. Product Portfolio
      • 12.13.2.2. Collaborations

13. INTERVIEW TRANSCRIPTS

  • 13.1. Chapter Overview
    • 13.1.1. Vincent Brichard, Vice President, Immuno-Oncology, Celyad
    • 13.1.2. Peter Ho, Director, Process Development, Lion Biotechnologies
    • 13.1.3. Aino Kalervo, Competitive Intelligence Manager - Strategy & Business Development, Theravectys

14. CONCLUSION

  • 14.1. T-Cell Therapies: Unfurling Another Dimension of Immunotherapy
  • 14.2. Collaborative Efforts of Research and Industry to Drivethe Market
  • 14.3. Undoubtedly CAR-T Therapy is the Current Flag-Bearer
  • 14.4. Haematological Cancers and Solid Tumours are the Key Focus Areas
  • 14.5. Innovative Technological Platforms have Emerged as Vital Enablers
  • 14.6. Anticipated Market Success Backed up by Progressive Pipelines and VC Funding

15. APPENDIX I: TABULATED DATA

APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures:

  • Figure 3.1: The Four Pillars of Cancer Therapy
  • Figure 3.2: Differences between Active and Passive Immunotherapy
  • Figure 3.3: Differences between Specific and Non-Specific Immunotherapy
  • Figure 3.4: 3Es of the Immune System
  • Figure 3.5: Strategies for Redirecting T-Cells
  • Figure 3.6: Targeted Therapeutic Areas in the T-Cell Market
  • Figure 3.7: T-Cell Therapy: Benefits and Roadblocks
  • Figure 4.1: T-Cell Immunotherapy Pipeline: Distribution by Type of Product
  • Figure 4.2: T-Cell Immunotherapy Pipeline: Distribution by Type of Developer
  • Figure 4.3: T-Cell Immunotherapy Pipeline: Distribution by Type of Developer across CAR-Ts, TCRs and TILs
  • Figure 4.4: T-Cell Immunotherapy Pipeline: Distribution by Phase of Development (Clinical/Preclinical)
  • Figure 4.5: T-Cell Immunotherapy Pipeline: Distribution by Phase of Development (PI/II/III/Preclinical)
  • Figure 4.6: T-Cell Immunotherapy Pipeline: Distribution by Phase of Development (PI/II/III/Preclinical) across CAR-Ts, TCRs and TILs
  • Figure 4.7: T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area
  • Figure 4.8: T-Cell Immunotherapy Pipeline: Distribution by Target Therapeutic Area across CAR-Ts, TCRs and TILs
  • Figure 4.9: T-Cell Immunotherapy Pipeline: Active Industry Players in Clinical Development
  • Figure 4.10: T-Cell Immunotherapy Pipeline: Active Industry Players in Preclinical Development
  • Figure 4.11: CAR-T Cell Therapy Pipeline: Distribution by Target Antigens
  • Figure 4.12: TCR Therapy Pipeline: Distribution by Target Antigens
  • Figure 5.1: Historical Timeline: Development of CAR-T cells
  • Figure 5.2: CAR-T: Mapping Prominent Researchers
  • Figure 5.3: Development of CAR-T Cells
  • Figure 5.4: Challenges Witnessed in CAR-T Therapy
  • Figure 5.5: CTL019: Industry Sponsored Clinical Trial Design
  • Figure 5.6: CTL019: Non-Industry Sponsored Clinical Trial Design
  • Figure 5.7: JCAR Series: Clinical Trial Design
  • Figure 5.8: JCAR: Planned Clinical Trials
  • Figure 5.9: KTE-C19: Clinical Trial Design
  • Figure 5.10: Manufacturing CD19 CAR-T Cells: Process Comparison
  • Figure 5.11: CD19 CAR: Clinical Trial Design
  • Figure 5.12: EGFRvIII CAR: Clinical Trial Design
  • Figure 6.1: TCR: Mapping Prominent Researchers
  • Figure 6.2: Development of TCR Based Therapies
  • Figure 6.3: NY-ESO-TCR: Clinical Trial Design
  • Figure 6.4: MAGE A3/A6 TCR: Clinical Trial Design
  • Figure 6.5: JTCR016: Clinical Trial Design
  • Figure 6.6: IMCgp100: Clinical Trial Design
  • Figure 7.1: TIL: Mapping Prominent Researchers
  • Figure 7.2: Process of Adoptive T-Cell Therapy Using TILs
  • Figure 7.3: LN-144: Clinical Trial Design
  • Figure 8.1: Overall T-Cell Therapy Market (USD Million)
  • Figure 8.2: T-Cell Therapy Market, Share of Sub-segments: Base Scenario 2020, 2025 and 2030 (USD Million)
  • Figure 8.3: Overall CAR-T Market Forecast: Base Scenario (USD Million)
  • Figure 8.4: CTL019: Current Status by Highest Phase of Development
  • Figure 8.5: CTL019 Sales Forecast: Base Scenario (USD Million)
  • Figure 8.6: KTE-C19: Current Status by Highest Phase of Development
  • Figure 8.7: KTE-C19 Sales Forecast: Base Scenario (USD Million)
  • Figure 8.8: CD 19 CAR-T Sales Forecast: Base Scenario (USD Million)
  • Figure 8.9: EGFR CAR-T Sales Forecast: Base Scenario (USD Million)
  • Figure 8.10: CD30 CAR-T Sales Forecast: Base Scenario (USD Million)
  • Figure 8.11: Anti-CD19 CAR-T Vector Transduced T-Cells Sales Forecast: Base Scenario (USD Million)
  • Figure 8.12: Anti-CD20 CAR-T Vector Transduced T-Cells Sales Forecast: Base Scenario (USD Million)
  • Figure 8.13: CD19 EBV CAR-T Sales Forecast: Base Scenario (USD Million)
  • Figure 8.14: EGFRvIII Sales Forecast: Base Scenario (USD Million)
  • Figure 8.15: JCAR017 Sales Forecast: Base Scenario (USD Million)
  • Figure 8.16: JCAR0XX Sales Forecast: Base Scenario (USD Million)
  • Figure 8.17: Overall TCR Market Forecast: Base Scenario (USD Million)
  • Figure 8.18: IMCgp100: Current Status by Highest Phase of Development
  • Figure 8.19: IMCgp100 Sales Forecast: Base Scenario (USD Million)
  • Figure 8.20: NY-ESO-1 TCR Sales Forecast: Base Scenario (USD Million)
  • Figure 8.21: HPV-16E6-TCR Sales Forecast: Base Scenario (USD Million)
  • Figure 8.22: NY-ESO-1 TCR: Current Status by Highest Phase of Development
  • Figure 8.23: NY-ESO-1 TCR Sales Forecast: Base Scenario (USD Million)
  • Figure 8.24: ALT-801 Sales Forecast: Base Scenario (USD Million)
  • Figure 8.25: WT-1 TCR Sales Forecast: Base Scenario (USD Million)
  • Figure 8.26: JTCR016: Current Status by Highest Phase of Development
  • Figure 8.27: JTCR016 Sales Forecast: Base Scenario (USD Million)
  • Figure 8.28: MAGE A3/A6 Sales Forecast: Base Scenario (USD Million)
  • Figure 8.29: MAGE A3 Sales Forecast: Base Scenario (USD Million)
  • Figure 8.30: Overall TIL Market Forecast: Base Scenario (USD Million)
  • Figure 8.31: LN-144 Sales Forecast: Base Scenario (USD Million)
  • Figure 8.32: TIL Therapy (Nantes University) Sales forecast: Base Scenario (USD Million)
  • Figure 8.33: TIL Therapy (Netherland University) Sales Forecast: Base Scenario (USD Million)
  • Figure 9.1: Most Common Types of Leukaemia
  • Figure 9.2: Leukaemia: Global Epidemiological Distribution
  • Figure 9.3: Lymphoma: Global Epidemiological Distribution
  • Figure 9.4: Multiple Myeloma: Global Epidemiological Distribution
  • Figure 9.5: Melanoma: Global Epidemiological Distribution
  • Figure 9.6: Bladder Cancer: Global Epidemiological Distribution
  • Figure 9.7: Kidney Cancer: Global Epidemiological Distribution
  • Figure 9.8: Ovarian Cancer: Global Epidemiological Distribution
  • Figure 9.9: Breast Cancer: Global Epidemiological Distribution
  • Figure 10.1: Applications of Genome Editing
  • Figure 10.2: Emerging Genome Editing Technologies
  • Figure 10.3: Emerging Design Technologies
  • Figure 10.4: Properties of Enhanced T-Cell Platform
  • Figure 10.5: Comparative Landscape: CAR-T Platforms
  • Figure 11.1: T-Cell Therapies Funding: Cumulative Number of Investments by Year, 2007-2015
  • Figure 11.2: T-Cell Therapies Funding: Cumulative Amount Invested by Year, 2007-2015 (USD Million)
  • Figure 11.3: T-Cell Therapies Funding: Distribution of Instances by Type of Funding
  • Figure 11.4: T-Cell Therapies Funding: Distribution of Amount Invested by Type of Funding (USD Million)
  • Figure 12.1: Adaptimmune: VC Funding Instances (USD Million)
  • Figure 12.2: Altor BioScience: VC Funding Instances (USD Million)
  • Figure 12.3: Cellectis: VC Funding Instances (USD Million)
  • Figure 12.4: Juno Therapeutics: VC Funding Instances (USD Million)
  • Figure 12.5: Kite Pharma: VC Funding Instances (USD Million)
  • Figure 12.6: Novartis: Sales, 2009-2014 (USD Billion)
  • Figure 12.7: Novartis: Sales by Operating Segments, 2014 (USD Billion)
  • Figure 12.8: Takara Bio: Sales, 2010-2014 (YEN Million)
  • Figure 12.9: Takara Bio: Sales by Operating Segments, 2014(YEN Million, %)
  • Figure 12.10: Unum Therapeutics: VC Funding Instances (USD Million)
  • Figure 12.11: Treatment Process Followed Using the Antibody Coupled T-Cell Receptor (ACTR) Technology
  • Figure 14.1: T-Cell Therapy Market Landscape: Industry Participants
  • Figure 14.2: T-Cell Therapy Market Landscape: Non-Industry Participants
  • Figure 14.3: T-Cell Immunotherapy Market Forecast: Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)

List of Tables:

  • Table 3.1: FDA Approved Antibody Based Therapeutics for Cancer
  • Table 3.2: Features of Retrovirus
  • Table 3.3: Features of Lentivirus
  • Table 4.1: T-Cell Immunotherapy Pipeline
  • Table 4.2: Other T-Cell Immunotherapeutics under Development
  • Table 5.1: Key Characteristics of CAR-T cells
  • Table 5.2: Comparison between 1st and 2nd Generation CARs
  • Table 5.3: Grading Criteria for CRS
  • Table 5.4: Safety Switches under Development for CAR-T Therapy
  • Table 5.5: CD19 CAR-T Cells: Preclinical Results
  • Table 5.6: Other Targets under Clinical/Preclinical Studies for CAR-T Therapy
  • Table 5.7: CTL019: Current Status of Development
  • Table 5.8: JCAR Series: Molecules in Clinical Development
  • Table 5.9: JCAR Series: CAR-T Design
  • Table 5.10: JCAR: Current Status of Development
  • Table 5.11: JCAR: Dosage Regimen
  • Table 5.12: KTE-C19: Current Status of Development
  • Table 5.13: CD19 CAR: Current Status of Development
  • Table 5.14: EGFRvIII CAR-T: Current Status of Development
  • Table 6.1: Differences between CAR-T and TCR Based Therapies
  • Table 6.2: NY-ESO-1 TCR: Current Status of Development
  • Table 6.3: MAGE A3/A6: Current Status of Development
  • Table 6.4: JTCR016: Current Status of Development
  • Table 6.5: IMCgp100: Current Status of Development
  • Table 7.1: LN-144: Current Status of Development
  • Table 7.2: Patent Portfolio
  • Table 8.1: T-Cell Immunotherapy: Market Potential of Candidates
  • Table 9.1: Comparison of Hodgkin's and Non-Hodgkin's Lymphoma
  • Table 9.2: Comparison of Marketed Targeted Therapeutics: Leukaemia
  • Table 9.3: Comparison of Marketed Targeted Therapeutics: Lymphoma
  • Table 9.4: Targets under Investigational Trials: Leukaemia
  • Table 9.5: Targets under Investigational Trials:Lymphoma
  • Table 9.6: Comparison of Marketed Targeted Therapeutics: Multiple Myeloma
  • Table 9.7: Targets under Investigational Trials:Multiple Myeloma
  • Table 9.8: Comparison of Marketed Targeted Therapeutics: Melanoma
  • Table 9.9: Historical Development of TIL Treatment Protocols at the National Cancer Institute
  • Table 9.10: Comparison of Marketed Targeted Therapeutics: Renal Cell Carcinoma
  • Table 9.11: Comparison of Marketed Therapeutics: Breast Cancer
  • Table 9.12: Targets under Investigational Trials:Breast Cancer
  • Table 10.1: CRISPR/Cas9: Research Publications, 2014/2015
  • Table 10.2: Editas Medicine: Funding Details
  • Table 10.3: Editas Medicine: Collaborations
  • Table 10.4: Intellia Therapeutics: Research Publications on CRISPR/Cas9
  • Table 10.5: Intellia Therapeutics: Funding Details
  • Table 10.6: Intellia Therapeutics: Collaborations
  • Table 10.7: CRISPR Therapeutics: Research Publications on CRISPR/Cas9
  • Table 10.8: CRISPR Therapeutics: Funding Details
  • Table 10.9: Cellectis: Funding Details
  • Table 10.10: Cellectis: Collaborations
  • Table 10.11: bluebird bio: Funding Details
  • Table 10.12: bluebird bio: Collaborations
  • Table 10.13: Unum Therapeutics: Funding Details
  • Table 10.14: Unum Therapeutics: Collaborations
  • Table 10.15: Intrexon: Funding Details
  • Table 10.16: Intrexon: Collaborations
  • Table 10.17: Switch Technologies: Research Publications from Bellicum Pharmaceuticals
  • Table 10.18: Bellicum Pharmaceuticals: Funding Details
  • Table 10.19: Theravectys: Funding Details
  • Table 11.1: List of Funding Rounds/Grants and Investors Involved
  • Table 12.1: Adaptimmune: T-Cell Immunotherapy Pipeline
  • Table 12.2: Adaptimmune: T-Cell Immunotherapy Collaborations
  • Table 12.3: Altor BioScience: T-Cell Immunotherapy Pipeline
  • Table 12.4: Altor BioScience: T-Cell Immunotherapy Collaborations
  • Table 12.5: bluebird bio: T-Cell Immunotherapy Pipeline
  • Table 12.6: bluebird bio: T-Cell Immunotherapy Collaborations
  • Table 12.7: Cellectis: T-Cell Immunotherapy Pipeline
  • Table 12.8: Cellectis: T-Cell Immunotherapy Collaborations
  • Table 12.9: Cell Therapy Catapult: T-Cell Immunotherapy Pipeline
  • Table 12.10: Cell Therapy Catapult: T-Cell Immunotherapy Collaborations
  • Table 12.11: Juno Therapeutics: T-Cell Immunotherapy Pipeline
  • Table 12.12: Juno Therapeutics: T-Cell Immunotherapy Collaborations
  • Table 12.13: Kite Pharma: T-Cell Immunotherapy Pipeline
  • Table 12.14: Kite Pharma: T-Cell Immunotherapy Collaborations
  • Table 12.15: Lion Biotechnologies: T-Cell Immunotherapy Pipeline
  • Table 12.16: Lion Biotechnologies: T-Cell Immunotherapy Collaborations
  • Table 12.17: Novartis: T-Cell Immunotherapy Pipeline
  • Table 12.18: Novartis: T-Cell Immunotherapy Collaborations
  • Table 12.19: Takara Bio: T-Cell Immunotherapy Pipeline
  • Table 12.20: Takara Bio: T-Cell Immunotherapy Collaborations
  • Table 12.21: Unum Therapeutics: T-Cell Immunotherapy Pipeline
  • Table 12.22: Unum Therapeutics: T-Cell Immunotherapy Collaborations
  • Table 12.23: Bellicum Pharmaceuticals: T-Cell Immunotherapy Pipeline
  • Table 12.24: Cellular Biomedicine Group: T-Cell Immunotherapy Pipeline
  • Table 12.25: Cellular Biomedicine Group: T-Cell Immunotherapy Collaborations
  • Table 15.1: T-Cell Therapy Pipeline: Distribution by Type of Product
  • Table 15.2: T-Cell Therapy Pipeline: Distribution by Type of Developer
  • Table 15.3: T-Cell Immunotherapy Pipeline: Comparison of Distribution by Type of Developer across CAR-Ts, TCRs and TILs
  • Table 15.4: T-Cell Therapy Pipeline: Distribution by Phase of Development (Clinical/Preclinical)
  • Table 15.5: T-Cell Therapy Pipeline: Distribution by Phase of Development (PI/II/III/Preclinical)
  • Table 15.6: T-Cell Therapy Pipeline: Comparison of Distribution by Phase of Development (PI/II/III/Preclinical) across CAR-Ts, TCRs and TILs
  • Table 15.7: T-Cell Therapy Pipeline: Distribution by Target Therapeutic Area
  • Table 15.8: T-Cell Therapy Pipeline: Comparison of Distribution by Target Therapeutic Area across CAR-Ts, TCRs and TILs
  • Table 15.9: T-Cell Therapy: Active Players in Clinical Development
  • Table 15.10: T-Cell Therapy: Active Players in Preclinical Development
  • Table 15.11: CAR-T Therapy: Distribution by Targets
  • Table 15.12: TCR Therapy: Distribution by Targets
  • Table 15.13: Overall T-Cell Therapy Market (USD Million)
  • Table 15.14: T-Cell Therapy Market, Share of Sub-segments: 2020, 2025 and 2030 (USD Million)
  • Table 15.15: Overall CAR-T Market Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.16: CTL019 Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.17: KTE-C19 Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.18: CD 19 CAR T Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.19: EGFR CAR-T Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.20: CD30 CAR-T Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.21: Anti-CD19 CAR-T Vector Transduced T-Cells Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.22: Anti-CD20 CAR-T Vector Transduced T-Cells Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.23: CD19 EBV CAR-T Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.24: EGFRvIII Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.25: JCAR017 Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.26: JCAR0XX Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.27: Overall TCR Market Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.28: IMCgp100 Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.29: NY-ESO-1 TCR Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.30: HPV-16E6-TCR Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.31: NY-ESO-1 TCR Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.32: ALT-801 Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.33: WT-1 TCR Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.34: JTCR016 Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.35: MAGE A3/A6 Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.36: MAGE A3 Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.37: Overall TIL Market Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.38: LN-144 Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.39: TIL Therapy (Nantes University) Sales forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.40: TIL Therapy (Netherlands University) Sales Forecast: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 15.41: T-Cell Therapies Funding: Cumulative Number of Investments by Year, 2007-2015
  • Table 15.42: T-Cell Therapies Funding: Cumulative Amount Invested by Year, 2007-2015 (USD Million)
  • Table 15.43: T-Cell Therapies Funding: Distribution of Instances by Type of Funding
  • Table 15.44: T-Cell Therapies Funding: Distribution of Amount Invested by Type of Funding (USD Million)
  • Table 15.45: Adaptimmune: VC Funding Instances (USD Million)
  • Table 15.46: Altor BioScience: VC Funding Instances (USD Million)
  • Table 15.47: bluebird bio: VC Funding Instances (USD Million)
  • Table 15.48: Cellectis: VC Funding Instances (USD Million)
  • Table 15.49: Juno Therapeutics: VC Funding Instances (USD Million)
  • Table 15.50: Kite Pharma: VC Funding Instances (USD Million))
  • Table 15.51: Novartis: Sales, 2010-2014 (USD Million)
  • Table 15.52: Novartis: Sales by Operating Segments, 2014 (USD Million)
  • Table 15.53: Takara Bio: Sales, 2010-2014 (YEN Million)
  • Table 15.54: Takara Bio: Sales by Operating Segments, 2014 (YEN Million)
  • Table 15.55: Unum Therapeutics: VC Funding Instances (USD Million)
  • Table 15.56: T-Cell Immunotherapy Market Forecast: Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Million)

List of Companies

Following companies and organisations have been mentioned in this report.

  • 1. Abingworth
  • 2. Abramson Cancer Center, University of Pennsylvania
  • 3. Acorn Campus Ventures
  • 4. Adaptimmune
  • 5. AFA Försäkring
  • 6. AGF Private Equity
  • 7. AgonOx
  • 8. Agreen Biotech
  • 9. Aju IB Investment
  • 10. Alaska Permanent Fund
  • 11. Alexandria Ventures
  • 12. Allos Therapeutics
  • 13. Altor BioScience
  • 14. Amgen
  • 15. Applied Immune Technologies
  • 16. Aquilo Capital Management
  • 17. ARCH Venture Partners
  • 18. Artax Biopharma
  • 19. AstraZeneca
  • 20. Atara Biotherapeutics
  • 21. Atlas Venture
  • 22. Autolus (spin off from UCL)
  • 23. AVG Ventures
  • 24. Banca Esperia
  • 25. BankInvest Biomedical Venture
  • 26. Bayer
  • 27. Baylor College of Medicine
  • 28. Bellicum Pharmaceuticals
  • 29. Bezos Expeditions
  • 30. Biogen
  • 31. BioNTech
  • 32. Biotecnol
  • 33. bluebird bio
  • 34. Bpifrance
  • 35. Brace Pharma Capital
  • 36. Bristol-Myers Squibb
  • 37. Broad Institute
  • 38. Broadfin Capital
  • 39. Cabaret Biotech
  • 40. California Institute for Regenerative Medicine
  • 41. California Institute of Technology
  • 42. California Stem Cell Agency
  • 43. Cancer Prevention and Research Institute of Texas
  • 44. Caribou Sciences
  • 45. CARsgen
  • 46. Casdin Capital
  • 47. Catalyst
  • 48. Celdara
  • 49. Celgene
  • 50. Cell Therapy Catapult
  • 51. Cellectis
  • 52. CELLforCURE
  • 53. Cellular Biomedicine Group
  • 54. Cellular Therapeutics
  • 55. Celyad
  • 56. Children with Leukaemia
  • 57. Chinese PLA General Hospital
  • 58. City of Hope Medical Center
  • 59. CLL Global Research Foundation Alliance
  • 60. Cold Genesys
  • 61. Conkwest
  • 62. Cowen Investment
  • 63. CRISPR Therapeutics
  • 64. CrunchFund
  • 65. Cyto Pulse
  • 66. Dartmouth College
  • 67. Deerfield Partners
  • 68. Dendreon Corporation
  • 69. Deutsche Krebshilfe
  • 70. Duke University
  • 71. Easton Capital
  • 72. EcoR1 Capital
  • 73. Editas Medicine
  • 74. Edmond Venture Capital
  • 75. Ehime University
  • 76. Eisai
  • 77. Eli Lilly
  • 78. Endocyte
  • 79. Erasmus University
  • 80. Eureka Therapeutics
  • 81. Fate Therapeutics
  • 82. Felicis Ventures
  • 83. Fidelity Biosciences
  • 84. Fiverings Co.
  • 85. Flagship Ventures
  • 86. Forbion Capital Partners
  • 87. Foresite Capital
  • 88. Formula Pharmaceuticals
  • 89. Fred Hutchinson Cancer Research Center
  • 90. Fujita Health University
  • 91. GammaCell Biotechnologies
  • 92. Genentech
  • 93. Genzyme (Sanofi)
  • 94. Genzyme Ventures
  • 95. Gilead Sciences
  • 96. GlaxoSmithKline
  • 97. Google Ventures
  • 98. Griffin Securities
  • 99. H. Lee Moffitt Cancer Center and Research Institute
  • 100. Harbinger Venture Capital
  • 101. Harvard University
  • 102. Healthcare investment company Syncona
  • 103. Heat Biologics
  • 104. Herlev Hospital
  • 105. High Line Venture Partners
  • 106. ImmunoCellular Therapeutics
  • 107. Immunocore
  • 108. Imperial Innovations
  • 109. IMS Health Capital
  • 110. Innovative Genome Initiative
  • 111. Intellia Therapeutics
  • 112. Intrexon
  • 113. Iowa State University
  • 114. Jannsen Biotech
  • 115. Jennison Associates
  • 116. Jichi Medical University
  • 117. JMP Securities
  • 118. John Hopkins University
  • 119. John Wayne Cancer Institute
  • 120. Jonsson Comprehensive Cancer Center
  • 121. JP Moulton Charitable Foundation
  • 122. Juno Therapeutics
  • 123. Karolinska University Hospital
  • 124. Keio University, School of Medicine
  • 125. Khosla Ventures
  • 126. Kite Pharma
  • 127. Leiden University Medical Center
  • 128. Leukemia and Lymphoma Society
  • 129. Ligand Pharmaceuticals
  • 130. Lion Biotechnologies
  • 131. Lonza Biologics
  • 132. Loyola University
  • 133. M.D. Anderson Cancer Center
  • 134. Massachusetts Institute of Technology
  • 135. MaxCyte
  • 136. Mayo Clinic
  • 137. Medigene
  • 138. Memorial Sloan Kettering Cancer Center
  • 139. Merck
  • 140. Merck Serono
  • 141. Mie University
  • 142. Millennium Pharmaceuticals
  • 143. MolMed
  • 144. Monash University
  • 145. Morphotek
  • 146. Mustang Therapeutics
  • 147. Nagoya University
  • 148. Nantes University Hospital
  • 149. Nantworks
  • 150. National Cancer Institute
  • 151. National Institute of Health
  • 152. National University of Singapore
  • 153. NeoStem
  • 154. New Enterprise Associates (NEA)
  • 155. New Leaf Venture
  • 156. Novartis
  • 157. Novartis Institute for Biomedical Research (NIBR)
  • 158. Novo A/S
  • 159. Oberland Capital Healthcare
  • 160. ODYSSEE Venture
  • 161. Ohio University
  • 162. Omega Funds
  • 163. Oncodesign Biotechnology
  • 164. OnCyte
  • 165. Ono Pharmaceutical Co.
  • 166. Onyx Pharmaceuticals
  • 167. Opexa Therapeutics
  • 168. Opus Bio
  • 169. OrbiMed Advisors
  • 170. Oxford BioMedica
  • 171. Partners Innovation Fund
  • 172. Pasteur Institute
  • 173. Peking University
  • 174. Perceptive Advisors
  • 175. Peter MacCallum Cancer Centre, University of Melbourne
  • 176. Pfizer
  • 177. Pharmacyclics
  • 178. Polaris Partners
  • 179. Pontifax
  • 180. Precision Biosciences/Pregenen
  • 181. Precision Genome Engineering
  • 182. Progenitor Cell Therapy
  • 183. Pure MHC
  • 184. QueensBridge Venture Partners
  • 185. Quogue Capital
  • 186. QVT Financial
  • 187. RA capital Management
  • 188. Ramius Capital Group
  • 189. Redmile Group
  • 190. Remeditex Ventures
  • 191. Renji Hospital
  • 192. Ridgeway Capital Partners
  • 193. Riverbank Capital Securities
  • 194. Roche
  • 195. Rock Spring Capital
  • 196. Roswell Park Cancer Institute
  • 197. Sabby Capital
  • 198. San Raffaele Hospital (OSR)
  • 199. Sanderling Ventures
  • 200. Sangamo Biosciences
  • 201. Sanofi-Genzyme BioVentures
  • 202. Seattle Children's Hospital
  • 203. Seattle Genetics
  • 204. Sectoral Asset Management
  • 205. Servier
  • 206. Shanghai Cancer Institute
  • 207. Sheba Medical Center
  • 208. Shenzhen Second People's Hospital
  • 209. Shionogi
  • 210. Silicon Valley Bank
  • 211. Sorrento Therapeutics
  • 212. Southwest Hospital
  • 213. Spectrum Pharmaceuticals
  • 214. SR One
  • 215. St. Jude Children's Research Hospital
  • 216. Stage Cell Therapeutics
  • 217. Statcom Co.
  • 218. Suma Ventures
  • 219. Sun Yat-Sen University
  • 220. Sunol Molecular Corporation
  • 221. SV Angel
  • 222. Swedish Cancer Society
  • 223. T. Rowe Price Associates
  • 224. Takara Bio
  • 225. T-Cell Factory
  • 226. Tel Aviv Sourasky Medical Centre
  • 227. TETHYS
  • 228. Texas Children's Hospital
  • 229. The Children's Hospital of Philadelphia
  • 230. The Christie NHS Foundation Trust
  • 231. The Methodist Hospital System
  • 232. The Netherlands Cancer Institute
  • 233. Theravectys
  • 234. Thermo Fisher Scientific
  • 235. Third Rock Ventures
  • 236. Three Arch Opportunity Fund
  • 237. TILT Biotherapeutics
  • 238. TNK Therapeutics (wholly owned subsidiary of Sorrento Therapeutics)
  • 239. Transposagen Biopharmaceuticals
  • 240. TVM Capital
  • 241. Two Blades Foundation
  • 242. TxCell
  • 243. University College of London
  • 244. University Health Network
  • 245. University of California
  • 246. University of Connecticut
  • 247. University of Florida
  • 248. University of Milano-Bicocca
  • 249. University of Minnesota
  • 250. University of Oxford
  • 251. Perelman School of Medicine, University of Pennsylvania
  • 252. University of Southern California
  • 253. University of Zurich
  • 254. Unum Therapeutics
  • 255. Uppsala University
  • 256. Valeant Pharmaceuticals
  • 257. venBio
  • 258. Venrock
  • 259. Versant Ventures
  • 260. Viking Global Investors
  • 261. Weill Cornell Medical College
  • 262. Weizmann Institute of Science
  • 263. Wellington Management
  • 264. X-Body
  • 265. Y Combinator
  • 266. Yuan Capital
  • 267. ZIOPHARM Oncology
Back to Top